iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
370.35 +0.45  +0.12% NASDAQ Jul 2, 8:00PM Delayed 2m USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 8.959B USD assets under management. It has an forecasted dividend yield of 0.22%, a forecasted PE ratio of 27.20, and a forecasted price to book value of 7.329. The fund has a net expense ratio of 0.48%, turns over its positions 33.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (3-31-15) 0.48%
Assets Under Management (7-2-15) 8.959B
30-Day Average Volume (7-2-15) 1.548M
Net Asset Value (7-2-15) 370.21
Discount or Premium to NAV (7-2-15) 0.04%
Turnover Ratio (3-31-15) 33.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.09% 0.09% 0.00%
Stock 99.91% 99.91% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of July 2, 2015

IBB Region Exposure

Americas 97.26%
North America 97.26%
Latin America 0.00%
Greater Europe 2.69%
United Kingdom 1.95%
Europe Developed 0.69%
Europe Emerging 0.00%
Africa/Middle East 0.05%
Greater Asia 0.04%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.04%
Market Classification
% Developed Markets 99.96%
% Emerging Markets 0.04%
As of July 1, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of July 2, 2015

IBB Stock Market Capitalization

Giant 33.80%
Large 29.75%
Medium 17.89%
Small 12.51%
Micro 5.96%
As of July 2, 2015
View More Holdings

IBB Top 10 Holdings

Name % Weight Price % Chg
Celgene Corp 8.23% 119.52 +1.10%
Gilead Sciences Inc 8.08% 115.04 -0.84%
Biogen Inc 8.03% 404.28 -0.28%
Amgen Inc 7.73% 153.26 -1.12%
Regeneron Pharmaceuticals Inc 7.07% 511.08 +0.90%
Alexion Pharmaceuticals Inc 4.46% 185.22 +0.74%
Illumina Inc 4.21% 220.07 -0.28%
Vertex Pharmaceuticals Inc 4.03% 131.26 +4.02%
Mylan NV 3.80% 70.12 +0.60%
Biomarin Pharmaceutical Inc 3.13% 136.84 +0.08%
As of July 2, 2015
Advertisement

IBB Basic Info

Style
Equity Style Large Cap/Growth
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%

IBB Manager Info

Name Tenure
Diane Hsiung 7.25 yrs
Greg Savage 7.25 yrs
Jennifer Hsui 2.67 yrs
Matthew Goff 1.51 yrs

IBB Risk Info

Beta 0.8463
Max Drawdown (All) 62.85%
Historical Sharpe (10y) 1.028
Historical Sortino (All) 0.8252
30-Day Rolling Volatility 19.53%
Daily Value at Risk (VaR) 1% (All) 4.85%
Monthly Value at Risk (VaR) 1% (All) 19.62%

IBB Fundamentals

Dividend Yield TTM (7-2-15) 0.03%
Weighted Average PE Ratio 27.69
Weighted Average Price to Sales Ratio 9.571
Weighted Average Price to Book Ratio 7.658
Weighted Median ROE 12.25%
Weighted Median ROA 3.74%
Forecasted Dividend Yield 0.22%
Forecasted PE Ratio 27.20
Forecasted Price to Sales Ratio 8.319
Forecasted Price to Book Ratio 7.329
Number of Holdings 146
As of July 2, 2015

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 13.60%
Forecasted Book Value Growth 13.42%
Forecasted Cash Flow Growth 30.00%
Forecasted Earnings Growth 36.57%
Forecasted Revenue Growth 15.23%
As of July 2, 2015

IBB Performance

  Returns Total Returns
1M 1.90% 1.91%
3M 9.02% 9.04%
6M 20.90% 20.91%
1Y 39.99% 40.04%
3Y 178.4% 179.9%
5Y 383.4% 389.8%
As of July 2, 2015

IBB Net Flows

1M 166.82M
3M 85.58M
6M 648.92M
YTD 648.92M
1Y 1.332B
3Y 2.489B
5Y 2.417B
As of June 30, 2015

IBB Attributes

Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2015
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.